Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
D 20.1 1.88% 0.37
NKTR closed up 1.88 percent on Thursday, April 22, 2021, on 72 percent of normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Up
Historical NKTR trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
200 DMA Support Bullish 0.00%
20 DMA Support Bullish 0.00%
Multiple of Ten Bullish Other 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 200 DMA Bullish 1.88%
Crossed Above 20 DMA Bullish 1.88%
MACD Bullish Signal Line Cross Bullish 1.88%
Outside Day Range Expansion 1.88%
NR7 Range Contraction 6.86%
Older End-of-Day Signals for NKTR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 17 hours ago
Up 2% about 17 hours ago
60 Minute Opening Range Breakout about 18 hours ago
20 DMA Support about 19 hours ago
200 DMA Support about 19 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Nektar Therapeutics Description

Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Pharmaceutical Immunology Clinical Development Pain Drugs Breast Cancer Pharmacology Treatment Of Breast Cancer Antibiotic Ovarian Cancer Opioid Chronic Pain Colorectal Cancer Neuropathic Pain Morphinans Cytokine Acute Pain Treatment Of Chronic Pain Constipation Pneumonia Anti Infectives Metastatic Breast Cancer Metastatic Colorectal Cancer Pegylation Opioid Antagonists Aminoglycoside Nektar Therapeutics Opioid Induced Constipation

Is NKTR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 26.75
52 Week Low 15.4
Average Volume 1,032,346
200-Day Moving Average 19.52
50-Day Moving Average 21.39
20-Day Moving Average 19.50
10-Day Moving Average 19.09
Average True Range 0.97
ADX 17.51
+DI 21.22
-DI 19.42
Chandelier Exit (Long, 3 ATRs ) 18.97
Chandelier Exit (Short, 3 ATRs ) 21.06
Upper Bollinger Band 20.67
Lower Bollinger Band 18.33
Percent B (%b) 0.76
BandWidth 11.99
MACD Line -0.49
MACD Signal Line -0.62
MACD Histogram 0.1319
Fundamentals Value
Market Cap 3.61 Billion
Num Shares 179 Million
EPS -2.44
Price-to-Earnings (P/E) Ratio -8.25
Price-to-Sales 17.93
Price-to-Book 2.52
PEG Ratio 3.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.57
Resistance 3 (R3) 21.52 20.98 21.33
Resistance 2 (R2) 20.98 20.61 21.01 21.24
Resistance 1 (R1) 20.54 20.37 20.76 20.59 21.16
Pivot Point 20.00 20.00 20.11 20.03 20.00
Support 1 (S1) 19.56 19.63 19.78 19.61 19.04
Support 2 (S2) 19.02 19.39 19.05 18.96
Support 3 (S3) 18.58 19.02 18.88
Support 4 (S4) 18.63